Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase

Clin Investig. 1993 Nov;71(11):918-23. doi: 10.1007/BF00185604.

Abstract

Serum beta 2-microglobulin, serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only albumin, serum beta 2-microglobulin and serum thymidine kinase added further prognostic information. When tested for efficiency in recognizing patients with poor (average survival time < 1 year) and good (average survival time > 5 years) prognosis, serum beta 2-microglobulin was best (80%), followed by total urinary protein (78%), hemoglobin (76%), and albumin (75%).

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cell Division / physiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / blood*
  • Multiple Myeloma / enzymology
  • Multiple Myeloma / mortality
  • Multivariate Analysis
  • Prognosis
  • Retrospective Studies
  • Serum Albumin / analysis
  • Survival Rate
  • Thymidine Kinase / blood*
  • beta 2-Microglobulin / metabolism*

Substances

  • Serum Albumin
  • beta 2-Microglobulin
  • Thymidine Kinase